Status:
COMPLETED
A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome
Lead Sponsor:
Rael
Collaborating Sponsors:
Citruslabs
Conditions:
Premenstrual Syndrome
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
This is a virtual single-group study that will last three menstrual cycles (approximately 12 weeks). During the first menstrual cycle, participants will take the supplement as needed (pro re nata) whe...
Eligibility Criteria
Inclusion
- Female, aged 18-40
- Self-reported moderate discomfort during menstruation related to pelvic cramps, bloating, fatigue, or mood swings.
- Self-reported symptoms during their menstrual cycle with gas, heartburn, and acid reflux
- Generally healthy - don't live with any uncontrolled chronic disease
- Has a menstrual cycle between 21 and 35 days in length
- Able to predict their menstrual cycle and timing of their menstruation
Exclusion
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Current use of any blood thinning medication
- Anyone with known severe allergic reactions.
- Women who are pregnant, breastfeeding, or attempting to become pregnant
- Unwilling to follow the study protocol.
- Anyone with a diagnosis of a condition relating to the menstrual cycle or reproductive system? e.g., polycystic ovary syndrome (PCOS), premenstrual dysphoric disorder (PMDD), endometriosis, etc.
- Anyone currently on hormonal birth control, or has been on hormonal birth control in the last 3 months
Key Trial Info
Start Date :
August 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06124326
Start Date
August 31 2023
End Date
January 20 2024
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Citruslabs
Santa Monica, California, United States, 90404